After reading Kazia's Annual Report, what I thought different this time was the absence of further partnering negotiations for Paxalisib.
However the Chairman's Letter only mentions Cantrixil's future development pathway.
"I have said previously that we consider the best path forward for Cantrixil to lie in a partnership with a larger company, one who shares our belief in the asset’s potential, and who brings to the partnership the wherewithal and technical resources to fully realise that potential. Our efforts on this front remain ongoing, and will be driven by final data from the phase I study, which we expect to have on hand in Q4 CY2020."
The CEO's Report also only mentions Cantrixil's future development pathway.
"We have said previously that we feel the potential of Cantrixil would be best realised with the support of a larger company, and the emerging data will no doubt help to fuel those discussions as we bring the phase I study to completion"
Regards.
KZA Price at posting:
$1.01 Sentiment: Buy Disclosure: Held
